---
search:
  boost: 3
---

# Cystic Fibrosis

This is a subcategory of Respiratory Agents.

## Decision Trees

- [Respiratory - Cystic Fibrosis- Non-Preferred - Bronchitol](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNEdPQ1hZVEs0TEdDNjRSSlBFVEk1STZZTSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Respiratory - Cystic Fibrosis- Preferred - Kalydeco, Orkambi, Symdeko, Trikafta](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOVI4OFFZUDZQVFdIN1Y0TlpBOExWWEtGUCQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                     | Generic Name                                              |         Quantity          |        Time (Days)        |
|:----------------------------------------------|:----------------------------------------------------------|:-------------------------:|:-------------------------:|
| Kalydeco <sup>PA QL</sup>                     | Ivacaftor Packet 50 MG & 75 MG                            | Determined pursuant to PA | Determined pursuant to PA |
| Kalydeco <sup>PA QL</sup>                     | Ivacaftor Tab 150 MG                                      | Determined pursuant to PA | Determined pursuant to PA |
| Orkambi <sup>PA QL</sup>                      | Lumacaftor / Ivacaftor (all strengths & formulations)     | Determined pursuant to PA | Determined pursuant to PA |
| Symdeko <sup>PA QL</sup>                      | Tezacaftor / Ivacaftor 100-150 MG & Ivacaftor 150 MG TBPK | Determined pursuant to PA | Determined pursuant to PA |
| Trikafta Pak <sup>AR</sup>, Tab <sup>PA</sup> |                                                           |                           |                           |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
|:--------------|:-------------|:--------:|:-----------:|
| Bronchitol    |              |          |             |

## Authorizations

**Length of Authorizations**: Initial 90 days; Subsequent 365 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

- Must be prescribed by or in consultation with a pulmonologist or infectious disease specialist
- Must provide documentation of the genetic mutation

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Bronchitol

Additional Bronchitol Criteria

- Must be used as an add-on maintenance therapy
- Must provide documentation of a completed Bronchitol Tolerance Test 

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patientâ€™s clinical response to treatment (adherence to
treatment demonstrated by claims history **AND** one or more of the following: FEV1,
weight gain, sweat chloride, pulmonary exacerbations, etc.) and ongoing safety
monitoring

**AR** - Trikafta Pak: a PA is required for patients 6 years and older

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7B73347C85-1D40-4514-80E9-9628185B51B4%7D&file=Denial%20Language%20Updated%2001012024.docx&action=embedview&mobiledirect=true&wdStartOn=92){:target="_blank" rel="noopener"} 

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=97){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=30){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
